u-card-img-1
News

2020 Annual report  

2020 marks the 10th anniversary of our first call for projects! Learn about our researchers, their scientific advances and how some of their discoveries have been translated into applications for human health.

Learn more
u-card-img-1
News
Publication in Nature Cancer

RNA epigenetics as a key regulator of cancer metastasis  

François Fuks and his team demonstrated the role of the regulation of RNA epigenetics by the FTO enzyme in the development of cancer metastasis.

Learn more
u-card-img-1
News
Spin-off creation

NeuVasQ: An innovative approach to fight against neurovascular and neurodegenerative diseases  

From disruptive research of scientific founder Benoit Vanhollebeke to the development of blood-brain barrier pharmaceuticals aiming at repairing neurovascular function and neurodegenerative diseases.

Learn more
u-card-img-1
News
Publication in Gut

D. welbionis : potential implications for metabolic diseases  

A new bacterium, made in Belgium

Patrice Cani  et his team discovered the properties displayed by D. welbionis, a new bacterium present in 70% of the population, that open the doors for potential treatment for type 2 diabetes, obesity and inflammatory diseases.

Learn more
u-card-img-1
News
Publication in Nature Communications

Wobble transfer RNA modifications optimize dynamic proteome expression  

Pierre Close and Francesca Rapino unfolded how the regulation of transfer RNAs and modification of their anticodon impacted the dynamics of protein synthesis and regulated protein folding and stability.

Learn more
u-card-img-1
News
Publication dans Science Advances

Maladies auto-immunes, des signatures moléculaire similaires au niveau des tissus cibles ?  

L'utilisation d'inhibiteurs de TYK2 - déjà utilisés pour d'autres maladies auto-immunes - protège les cellules β contre les dommages induits par le système immunitaire

Decio Eizirik  et son équipe décrivent des signatures moléculaires similaires entre différentes maladies auto-immunes, identifiant des voies clés qui pourraient être ciblées pour la thérapie.

Learn more
u-card-img-1
News
Publication in Nature

Cancer: Tumor driver promoting EMT, metastasis and resistance to therapy  

New therapy for FAT1 mutated cancers

Cédric Blanpain and his team identified the functions of FAT1, one of the most frequently mutated cancer gene drivers, uncovering that FAT1 mutations promote invasive features, metastasis and resistance to commonly used anti-cancer drugs

Learn more
u-card-img-1
News
The "Belgian Nobel Prize"

The Francqui-Collen Prize 2020 is awarded to Cédric Blanpain  

Prize awarded to a Belgian investigator less than 50 y.o. “who has made an important contribution to science augmenting the prestige of Belgium".”

Cédric Blanpain is awarded the Francqui-Collen Prize for his fundamental research in cancer and stem cells biology.

Learn more
u-card-img-1
News
Important collaboration agreement with Kaneka Eurogentec

From fundamental research on bacterial stress to the production of biomedicines.  

The use of biomedicines is disrupting current medicine

Kaneka and its Walloon subsidiary, Kaneka Eurogentec S.A., enter into a partnership with Jean-François Collet's laboratory  by funding a new joint research group at the Duve Institute.

Learn more
u-card-img-1
News
Déclarez-vous volontaire !

Luttons tous ensemble contre le Covid-19  

Boostons la recherche clinique

WELBIO lance aujourd’hui une plateforme digitale permettant aux citoyens de se déclarer volontaires pour des études cliniques relatives au Covid-19 : https://rechercheclinique.be/

Learn more
u-card-img-1
News
Publication in Science Translational Medicine

A new target and a potential cure of cardiac hypertrophy inspired from plant biology  

Blockade of transmembrane transport of hydrogen peroxide by cardiac Aquaporin-1 with Brahmi prevents myocardial remodelling

These results from the team of Jean-Luc Balligand  pave the way for the development of more potent molecules to block aquaporin and treat heart failure more efficiently.

Learn more
u-card-img-1
News
Publication in Gut

Targeting our second brain to fight diabetes  

A ‘jammer’ blocks communication between the gut and the brain

This jammer prevents proper regulation of sugar, causing insulin resistance in people with diabetes. Patrice Cani and colleagues also discovered that a lipid produced by our body helps preventing this dysfunction.

Learn more

Share this page